TL;DR: Aetna, a CVS Health company, modified CPB 0841 covering non-invasive measurement of advanced glycation end-products (AGEs), effective December 10, 2025. The policy confirms this technology is not covered — here's what your billing team needs to know before submitting claims.
If your practice has been billing or considering billing for non-invasive AGE measurement in diabetic patients, stop. The Aetna AGE measurement coverage policy under CPB 0841 in the Aetna system classifies this technology as experimental, investigational, or unproven across all measurement sites — skin, saliva, and tears. There is no path to reimbursement for this service under Aetna plans as of the December 10, 2025 effective date.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Non-invasive Measurement of Advanced Glycation End-products |
| Policy Code | CPB 0841 |
| Change Type | Modified |
| Effective Date | December 10, 2025 |
| Impact Level | Medium — affects endocrinology, primary care, and diabetes management practices billing Aetna |
| Specialties Affected | Endocrinology, Primary Care, Internal Medicine, Diabetes Care |
| Key Action | Do not bill Aetna for non-invasive AGE measurement — update charge capture and denial workflows before December 10, 2025 |
Aetna Non-Invasive AGE Measurement Coverage Criteria and Medical Necessity Requirements 2025
The short answer on medical necessity here is: there isn't any. Aetna's coverage policy under CPB 0841 does not recognize non-invasive measurement of advanced glycation end-products as medically necessary for any indication. That's not a soft exclusion or a prior authorization hurdle — it's a flat denial category.
Advanced glycation end-products are proteins or lipids that become glycated after exposure to sugars. Measuring them non-invasively — through the skin via autofluorescence, or through saliva and tear samples — has been marketed as a way to assess long-term glycemic control and cardiovascular risk in diabetic patients. The clinical pitch is compelling. The payer response is not.
Aetna reviewed the peer-reviewed literature and found it insufficient to support coverage. That means no prior authorization pathway exists. You cannot get this approved with supporting documentation, a letter of medical necessity, or a peer-to-peer review. Aetna simply does not cover it.
The ICD-10 codes ranging from E08.00 through E13.9 — the full diabetes mellitus spectrum — are the diagnosis codes associated with this policy. Patients with any form of diabetes are the target population for AGE testing. But the underlying diagnosis doesn't change the outcome. Even a well-documented diabetic patient with cardiovascular risk factors gets a denial under this policy.
If your billing team has been fielding questions from clinicians about whether Aetna covers AGE testing, the answer is no — and CPB 0841 is the policy to cite.
Aetna Non-Invasive AGE Measurement Exclusions and Non-Covered Indications
This entire policy is essentially an exclusion. Aetna classifies non-invasive AGE measurement as experimental, investigational, or unproven in every form it currently exists.
That language — "experimental, investigational, or unproven" — is the most complete denial bucket in the payer playbook. It means the payer is not just saying "not covered today." It means the evidence base hasn't cleared Aetna's threshold for clinical utility. Until the peer-reviewed literature catches up, the coverage policy won't move.
The three measurement modalities called out in CPB 0841 are:
| # | Excluded Procedure |
|---|---|
| 1 | Skin: Non-invasive autofluorescence-based skin AGE measurement |
| 2 | Saliva: AGE measurement from salivary samples |
| 3 | Tears: AGE measurement from tear samples |
All three are denied. There's no distinction between them in terms of coverage status — they all land in the same category.
The related policies — CPB 0070 (Diabetic Tests, Programs and Supplies) and CPB 0381 (Cardiovascular Disease Risk Tests) — are worth pulling if you're managing a broader diabetes or cardiology billing program. Covered diabetic testing under CPB 0070 is a completely separate lane from AGE measurement. Don't let a clinician assume that because standard diabetic testing is covered, AGE testing is too.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Non-invasive skin AGE measurement in diabetes patients | Not Covered — Experimental | E08.00–E13.9 | Classified as experimental/investigational; no prior auth pathway |
| Non-invasive saliva AGE measurement in diabetes patients | Not Covered — Experimental | E08.00–E13.9 | Classified as experimental/investigational; no prior auth pathway |
| Non-invasive tear AGE measurement in diabetes patients | Not Covered — Experimental | E08.00–E13.9 | Classified as experimental/investigational; no prior auth pathway |
| AGE measurement for cardiovascular risk assessment in diabetic patients | Not Covered — Experimental | E08.00–E13.9 | See also CPB 0381 for covered cardiovascular risk tests |
Aetna Non-Invasive AGE Measurement Billing Guidelines and Action Items 2025
The December 10, 2025 effective date means this policy is live now. If your team has any open workflows or charge capture rules touching AGE measurement, address them immediately.
| # | Action Item |
|---|---|
| 1 | Audit your charge capture for any AGE measurement service lines. If your EHR or billing system has a charge code built for non-invasive AGE testing under Aetna, flag it for removal or block it from submission. A claim going out the door for this service is a claim heading for denial. |
| 2 | Update your denial management workflows. If you receive Aetna denials citing CPB 0841, do not work these as standard medical necessity denials — there is no appeal path built on additional clinical documentation. The policy is categorical. Train your denials team to close these efficiently and educate the ordering provider rather than pursuing futile appeals. |
| 3 | Communicate with ordering physicians now. Endocrinologists, primary care physicians, and internists managing diabetic patients may not know Aetna's position. Send a brief internal note citing CPB 0841 and the December 10, 2025 effective date. This protects your practice from write-offs on services ordered in good faith. |
| 4 | Check CPB 0070 and CPB 0381 for covered alternatives. If a clinician is trying to assess glycemic control or cardiovascular risk in a diabetic patient, there are covered pathways. CPB 0070 covers standard diabetic testing supplies and programs. CPB 0381 governs cardiovascular disease risk tests. Direct clinicians to those policies for covered options. |
| 5 | Do not submit for prior authorization on this service. There is no prior authorization process for services Aetna classifies as experimental or investigational. Submitting a prior auth request wastes administrative time and won't change the outcome. The AGE measurement billing question under Aetna has one answer: don't bill it. |
| 6 | If your practice is involved in clinical research using AGE measurement, talk to your compliance officer. Research billing has separate rules. If AGE measurement is being performed as part of a study, your compliance officer needs to confirm the appropriate billing pathway — if any exists. Don't assume standard clinical billing rules apply. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Non-Invasive AGE Measurement Under CPB 0841
The policy data for CPB 0841 does not list specific CPT or HCPCS codes for non-invasive AGE measurement. This is meaningful on its own — it signals that this technology has not reached the level of standardized procedure coding. There's no CPT code widely accepted for non-invasive skin autofluorescence AGE testing or salivary/tear AGE measurement. If a vendor or device manufacturer is suggesting you submit under a specific code, verify that guidance with your billing consultant before submitting a single claim.
Key ICD-10-CM Diagnosis Codes
These are the ICD-10 codes associated with CPB 0841. They cover the full diabetes mellitus spectrum — the patient population for whom AGE measurement is typically ordered.
| Code Range | Description |
|---|---|
| E08.00–E13.9 | Diabetes mellitus (full range, all types and manifestations) |
Every diabetic diagnosis code your practice uses for endocrinology or diabetes management claims falls within this range. That's not a narrow policy — it covers virtually every diabetic patient your practice sees under Aetna.
The absence of a specific CPT or HCPCS code in this policy is actually a useful data point for billing teams. It means there's no "right" code to submit for this service. If you're seeing internal requests to find a code that works for AGE measurement under Aetna, the answer isn't a different code — it's a different service.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.